The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

被引:0
作者
Kaamar Azijli
Ingrid A. M. van Roosmalen
Jorn Smit
Saravanan Pillai
Masakazu Fukushima
Steven de Jong
Godefridus J. Peters
Irene V. Bijnsdorp
Frank A. E. Kruyt
机构
[1] University of Groningen,Department of Medical Oncology, University Medical Center Groningen
[2] VU University Medical Center,Department of Medical Oncology
[3] Taiho Pharmaceutical Co.,Tokushima Research Center
[4] Ltd.,undefined
来源
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词
TRAIL; TFT; Synergy; Apoptosis; NSCLC;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1273 / 1283
页数:10
相关论文
共 242 条
[1]  
Jemal A(2007)Cancer statistics, 2007 CA Cancer J Clin 57 43-66
[2]  
Siegel R(1995)New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression Chest 108 246-254
[3]  
Ward E(2008)Directing cancer cells to self-destruct with pro-apoptotic receptor agonists Nat Rev Drug Discov 7 1001-1012
[4]  
Murray T(2003)TRAIL and apoptosis induction by TNF-family death receptors Oncogene 22 8628-8633
[5]  
Xu J(2004)Cell death: critical control points Cell 116 205-219
[6]  
Thun MJ(2007)TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib Mol Cancer Ther 6 2103-2112
[7]  
Mountain CF(2010)Targeting apoptosis pathways in lung cancer Cancer Lett 332 359-368
[8]  
Ashkenazi A(2010)Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer Int J Biochem Cell Biol 42 210-213
[9]  
Wang S(2010)TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives Drug Resist Updat 13 2-15
[10]  
El-Deiry WS(2007)Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies Cancer Sci 98 779-789